Dewey Bailey, MD
Endocrinology, Diabetes & Metabolism · Roanoke, VANPI 1285628446
Payments from drug & device makers
Across 2,106 payments — averaging $306.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$266K
- Amgen$121K
- AstraZeneca$71K
- Lilly USA, LLC$40K
- Abbott$25K
- Johnson & Johnson$25K
- plus $96K from 52 others
What the payments were for
- Consulting fees$8,9631%
- Speaking & faculty fees$557,90686%
- Travel & lodging$41,6996%
- Food & beverage$36,5156%
- Education$1130%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$129,998
- RYBELSUS$84,954
- FARXIGA$69,455
- EVENITY$62,636
- JARDIANCE$59,693
- Prolia$37,354
- INVOKANA$24,315
- AFREZZA$22,751
- Repatha$17,831
- Tresiba$16,015
- Kerendia$15,392
- FREESTYLE LIBRE 3$12,821
- NEXLIZET$8,521
- NEXLETOL$8,521
- NATPARA (PARATHYROID HORMONE)$6,745
- Saxenda$5,076
- FreeStyle Libre 2$4,794
- Victoza$4,696
- RECORLEV$3,999
- FreeStyle Libre$2,850
How this compares
$645,255 in reported general payments places this provider in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 827 | $1,270,129 |
| JardianceEmpagliflozin | 569 | $610,575 |
| Tresiba Flextouch U-100Insulin Degludec | 515 | $427,953 |
| Tresiba Flextouch U-200Insulin Degludec | 203 | $335,840 |
| FarxigaDapagliflozin Propanediol | 235 | $302,035 |
| MounjaroTirzepatide | 210 | $283,768 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 138 | $210,940 |
| TrulicityDulaglutide | 148 | $195,045 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 139 | $168,072 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 113 | $126,070 |
| JanuviaSitagliptin Phosphate | 109 | $126,056 |
| RybelsusSemaglutide | 72 | $114,521 |
| Humalog Kwikpen U-200Insulin Lispro | 32 | $103,857 |
| Humalog Kwikpen U-100Insulin Lispro | 236 | $98,651 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $94,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Fiasp, Novolog | $266,168 | $1,496,0051,017 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Glyxambi | $24,010 | $848,190791 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $39,886 | $527,619476 claims |
| AstraZenecaFarxiga | $71,208 | $302,035235 claims |
| MerckJanuvia, Janumet Xr, Janumet | $154 | $216,341181 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $380 | $168,072139 claims |
| AmgenProlia | $121,487 | $90,00552 claims |
| Mannkind CorporationAfrezza | $24,327 | $57,08921 claims |
| BayerKerendia | $15,956 | $35,15422 claims |
| AbbVieSynthroid | $683 | $34,617502 claims |
| Johnson & JohnsonInvokana | $25,080 | $22,85918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Roanoke
- James MulindaRoanoke$788K
- Michael KochRoanoke$55K
- Carl BivensRoanoke$14K
- Domenica RubinoArlington$3M
- Suzanne Jan de BeurCharlottesville$1.5M
- Farhad ZangenehSterling$1.2M
- Ali IranmaneshSalem$1.1M
- Elias SirajNorfolk$884K
- Jeffrey SicatGlen Allen$657K
- James la RocqueChesapeake$576K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.